Loading
A trial testing whether a radiotherapy dose one sixth of the standard works as well for early follicular lymphoma when an antibody is given alongside it.
Two pieces of evidence pull in opposite directions here. The FoRT trial found 4 Gy of radiotherapy inferior to 24 Gy for indolent lymphoma on response and progression-free survival. The MIR study and TROG 99.03 found that adding an anti-CD20 antibody to localised radiotherapy improves outcomes, and the GAZAI study reported a high complete response rate with 2 by 2 Gy combined with obinutuzumab.
FORTplus tests whether the antibody makes the low dose safe. Its first question is the non-inferiority of 4 Gy given with an anti-CD20 antibody; if that holds, its second is whether obinutuzumab with low-dose radiotherapy is superior to rituximab with the standard dose, tested on the same set. The primary endpoint is morphological complete response, with primary completion estimated for 30 September 2027 at German sites.
The prize the trial is playing for is explicit in its protocol: a radiation dose reduced to 16 per cent of the standard, which would change how early follicular lymphoma is treated everywhere, including in settings where radiotherapy capacity is the binding constraint.
Confirms 24 Gy in 12 fractions as the optimal dose for indolent lymphoma when durable local control is the goal.
The evidence that early follicular lymphoma is less often confined to the radiation field than staging suggests, and that a short course of systemic treatment after radiotherapy reduces relapse. It is also the reason modern practice stages this disease with positron emission tomography.
24 Gy in 12 fractions is the standard radiotherapy dose for indolent lymphoma when durable local control is the aim; 4 Gy remains useful for palliation.
Shares Complete response, Obinutuzumab, CD20, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.
Shares Complete response, Obinutuzumab, CD20, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.
Shares GALLIUM, Obinutuzumab, CD20, Rituximab and the tag lymphoma-evidence.
Shares GALLIUM, CD20, Rituximab, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.
Shares GALLIUM, Obinutuzumab, CD20, Rituximab and the tag lymphoma-evidence.
Shares Complete response, CD20, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Follicular lymphoma and the tag lymphoma-evidence.
Shares Non-inferiority trial, Rituximab, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Toxicity and quality of life are undervalued and the tag lymphoma-evidence.
Shares CD20, Rituximab, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Follicular lymphoma and the tag lymphoma-evidence.